Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1951 11
1952 12
1953 9
1954 13
1955 8
1956 9
1957 14
1958 17
1959 8
1960 20
1961 58
1962 81
1964 8
1965 107
1966 155
1967 162
1968 169
1969 164
1970 167
1971 203
1972 217
1973 190
1974 173
1975 153
1976 153
1977 142
1978 125
1979 181
1980 170
1981 197
1982 207
1983 258
1984 257
1985 260
1986 256
1987 356
1988 469
1989 630
1990 590
1991 670
1992 830
1993 876
1994 852
1995 1906
1996 2962
1997 3170
1998 3552
1999 3678
2000 3592
2001 4034
2002 4082
2003 4127
2004 4226
2005 4959
2006 5093
2007 5450
2008 5851
2009 5350
2010 5707
2011 6371
2012 6722
2013 6960
2014 7219
2015 7465
2016 7437
2017 7388
2018 7034
2019 3500
2020 128
Text availability
Article attribute
Article type
Publication date

Search Results

125,332 results
Results by year
Filters applied: . Clear all
Page 1
Proton pump inhibitors: Risks of long-term use.
Eusebi LH, et al. J Gastroenterol Hepatol 2017 - Review. PMID 28092694
Proton pump inhibitors are among the most commonly prescribed classes of drugs, and their use is increasing, in particular for long-term treatment, often being over-prescribed and used for inappropriate conditions. ...The most recent literature regarding these adverse effects and their association with long-term proton pump inhibitor treatment is reviewed, and the mechanisms through which these possible complications might develop are discussed....
Proton pump inhibitors are among the most commonly prescribed classes of drugs, and their use is increasing, in particular for long-t …
Entropically driven Polymeric Enzyme Inhibitors by End-Group directed Conjugation.
Hijazi M, et al. Chemistry 2018. PMID 29385291
A new generic concept for polymeric enzyme inhibitors is presented using the example of poly(2-methyl-2-oxazoline) (PMOx) terminated with an iminodiacetate (IDA) function. ...This kind of inhibitor offers new avenues towards designing bioactive compounds....
A new generic concept for polymeric enzyme inhibitors is presented using the example of poly(2-methyl-2-oxazoline) (PMOx) term …
Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.
Graham DY and Tansel A. Clin Gastroenterol Hepatol 2018. PMID 28964908 Free PMC article.
Although proton pump inhibitors (PPIs) are widely used, their relative potency and ideal dosing regimens remain unclear. We analyzed data from randomized clinical trials that performed pH testing in patients receiving solid-dose PPI formulations (omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole) for a minimum of 5 days. ...
Although proton pump inhibitors (PPIs) are widely used, their relative potency and ideal dosing regimens remain unclear. We analyzed …
Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands.
Rodríguez-Soacha DA, et al. Eur J Med Chem 2019 - Review. PMID 31401465
In particular, latest findings in the field of MTDL design targeting both an enzyme and a receptor are presented for different diseases such as Alzheimer's disease (AD), depression, addiction, glaucoma, non-alcoholic steatohepatitis and pain and inflammation. ...
In particular, latest findings in the field of MTDL design targeting both an enzyme and a receptor are presented for different diseas …
Time-dependent CYP inhibition.
Riley RJ, et al. Expert Opin Drug Metab Toxicol 2007 - Review. PMID 17269894
Time-dependent inhibition (TDI) of CYP refers to a change in potency during an in vitro incubation or dosing period in vivo. Potential mechanisms include the formation of inhibitory metabolites and mechanism-based inhibition (MBI). In vitro experiments are configured to assess TDI and MBI is inferred, at least initially. ...
Time-dependent inhibition (TDI) of CYP refers to a change in potency during an in vitro incubation or dosing period in vivo. Potentia …
Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
Ong WY, et al. ACS Chem Neurosci 2015 - Review. PMID 25891385
Several old and new synthetic inhibitors of PLA2, including fatty acid trifluoromethyl ketones; methyl arachidonyl fluorophosphonate; bromoenol lactone; indole-based inhibitors; pyrrolidine-based inhibitors; amide inhibitors, 2-oxoamides; 1,3-disubstituted propan-2-ones and polyfluoroalkyl ketones as well as phytochemical based PLA2 inhibitors including curcumin, Ginkgo biloba and Centella asiatica extracts have been discovered and used for the treatment of neurological disorders in cell culture and animal model systems. The purpose of this review is to summarize information on selective and potent synthetic inhibitors of PLA2 as well as several PLA2 inhibitors from plants, for treatment of oxidative stress and neuroinflammation associated with the pathogenesis of neurological disorders....
Several old and new synthetic inhibitors of PLA2, including fatty acid trifluoromethyl ketones; methyl arachidonyl fluorophosphonate; …
Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium.
Chłopicki S and Gryglewski RJ. Pharmacol Rep 2005 - Review. PMID 16415489
In modern cardiovascular pharmacology, inhibitors of angiotensin converting enzyme (ACE-I) or inhibitors of HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase (statins) are among the most widely used cardiovascular drugs. ...They were respectively targeted to inhibit ACE in blood or to inhibit HMG-CoA reductase in the liver. Surprisingly, these two classes of drugs apart from their classic mechanisms of action exert pleiotropic endothelial actions, which involve the inhibition of ACE or HMG-CoA reductase within the endothelium, as well as other less understood endothelial mechanisms. ...
In modern cardiovascular pharmacology, inhibitors of angiotensin converting enzyme (ACE-I) or inhibitors of HydroxyMeth …
Unknown face of known drugs - what else can we expect from angiotensin converting enzyme inhibitors?
Wzgarda A, et al. Eur J Pharmacol 2017 - Review. PMID 28087255
Angiotensin-converting enzyme inhibitors (ACEI) are drugs most commonly used in the modulation of RAS activity. ACEI have been extensively described as effective in the treatment of hypertension among adults, but also as drugs delaying progression in diabetic nephropathy and reducing mortality in left ventricular dysfunction and congestive heart failure. ...
Angiotensin-converting enzyme inhibitors (ACEI) are drugs most commonly used in the modulation of RAS activity. ACEI have been …
125,332 results
Jump to page
Feedback